184 related articles for article (PubMed ID: 34873460)
1. Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies.
Chen D; You F; Xiang S; Wang Y; Li Y; Meng H; An G; Zhang T; Li Z; Jiang L; Wu H; Sheng B; Zhang B; Yang L
Am J Cancer Res; 2021; 11(11):5263-5281. PubMed ID: 34873460
[TBL] [Abstract][Full Text] [Related]
2. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.
Zhang M; Chen D; Fu X; Meng H; Nan F; Sun Z; Yu H; Zhang L; Li L; Li X; Wang X; Wang M; You F; Li Z; Chang Y; Zhou Z; Yan J; Li J; Wu X; Wang Y; Wang Y; Xiang S; Chen Y; Pan G; Xu H; Zhang B; Yang L
Clin Cancer Res; 2022 Jul; 28(13):2830-2843. PubMed ID: 35435984
[TBL] [Abstract][Full Text] [Related]
3. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies.
Png YT; Vinanica N; Kamiya T; Shimasaki N; Coustan-Smith E; Campana D
Blood Adv; 2017 Nov; 1(25):2348-2360. PubMed ID: 29296885
[TBL] [Abstract][Full Text] [Related]
4. Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection.
Jiang J; Chen J; Liao C; Duan Y; Wang Y; Shang K; Huang Y; Tang Y; Gao X; Gu Y; Sun J
Leukemia; 2023 Aug; 37(8):1660-1670. PubMed ID: 37391486
[TBL] [Abstract][Full Text] [Related]
5. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
Gomes-Silva D; Srinivasan M; Sharma S; Lee CM; Wagner DL; Davis TH; Rouce RH; Bao G; Brenner MK; Mamonkin M
Blood; 2017 Jul; 130(3):285-296. PubMed ID: 28539325
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.
Watanabe N; Mo F; Zheng R; Ma R; Bray VC; van Leeuwen DG; Sritabal-Ramirez J; Hu H; Wang S; Mehta B; Srinivasan M; Scherer LD; Zhang H; Thakkar SG; Hill LC; Heslop HE; Cheng C; Brenner MK; Mamonkin M
Mol Ther; 2023 Jan; 31(1):24-34. PubMed ID: 36086817
[TBL] [Abstract][Full Text] [Related]
7. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.
You F; Wang Y; Jiang L; Zhu X; Chen D; Yuan L; An G; Meng H; Yang L
Am J Cancer Res; 2019; 9(1):64-78. PubMed ID: 30755812
[TBL] [Abstract][Full Text] [Related]
8. Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody.
Ye J; Jia Y; Tuhin IJ; Tan J; Monty MA; Xu N; Kang L; Li M; Lou X; Zhou M; Fang X; Shao J; Zhu H; Yan Z; Yu L
Mol Ther Oncolytics; 2022 Mar; 24():719-728. PubMed ID: 35317521
[TBL] [Abstract][Full Text] [Related]
9. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study.
Hu Y; Zhou Y; Zhang M; Zhao H; Wei G; Ge W; Cui Q; Mu Q; Chen G; Han L; Guo T; Cui J; Jiang X; Zheng X; Yu S; Li X; Zhang X; Chen M; Li X; Gao M; Wang K; Zu C; Zhang H; He X; Wang Y; Wang D; Ren J; Huang H
Cell Res; 2022 Nov; 32(11):995-1007. PubMed ID: 36151216
[TBL] [Abstract][Full Text] [Related]
10. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
Dai Z; Mu W; Zhao Y; Cheng J; Lin H; Ouyang K; Jia X; Liu J; Wei Q; Wang M; Liu C; Tan T; Zhou J
Signal Transduct Target Ther; 2022 Mar; 7(1):85. PubMed ID: 35332132
[TBL] [Abstract][Full Text] [Related]
11. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies.
Freiwan A; Zoine JT; Crawford JC; Vaidya A; Schattgen SA; Myers JA; Patil SL; Khanlari M; Inaba H; Klco JM; Mullighan CG; Krenciute G; Chockley PJ; Naik S; Langfitt DM; Mamonkin M; Obeng EA; Thomas PG; Gottschalk S; Velasquez MP
Blood; 2022 Dec; 140(25):2684-2696. PubMed ID: 35914226
[TBL] [Abstract][Full Text] [Related]
12. SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies.
Wei W; Ma H; Yang D; Sun B; Tang J; Zhu Y; Chen X; Huang X; Liu J; Hu Z; Liu T; Zou L; Zhao X
Blood Adv; 2023 Jul; 7(13):2941-2951. PubMed ID: 36848638
[TBL] [Abstract][Full Text] [Related]
13. Base-edited CAR T cells for combinational therapy against T cell malignancies.
Georgiadis C; Rasaiyaah J; Gkazi SA; Preece R; Etuk A; Christi A; Qasim W
Leukemia; 2021 Dec; 35(12):3466-3481. PubMed ID: 34035409
[TBL] [Abstract][Full Text] [Related]
14. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
Cooper ML; DiPersio JF
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101097. PubMed ID: 31779968
[TBL] [Abstract][Full Text] [Related]
16. Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances.
Liu J; Zhang Y; Guo R; Zhao Y; Sun R; Guo S; Lu W; Zhao M
Front Immunol; 2023; 14():1170968. PubMed ID: 37215124
[TBL] [Abstract][Full Text] [Related]
17. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
18. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.
Gomes-Silva D; Atilla E; Atilla PA; Mo F; Tashiro H; Srinivasan M; Lulla P; Rouce RH; Cabral JMS; Ramos CA; Brenner MK; Mamonkin M
Mol Ther; 2019 Jan; 27(1):272-280. PubMed ID: 30391141
[TBL] [Abstract][Full Text] [Related]
19. Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells.
Xie L; Gu R; Yang X; Qiu S; Xu Y; Mou J; Wang Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Hum Gene Ther; 2023 Dec; 34(23-24):1257-1272. PubMed ID: 37861302
[TBL] [Abstract][Full Text] [Related]
20. [Killing Effect of A CD7 Chimeric Antigen Receptor-Modified NK-92MI Cell Line on CD7-Positive Hematological Malignant Cells].
Zhu XY; Liu X; Wang XB; Wang AY; Wang M; Liu NN; You FT; Pan GF; Yang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1367-1375. PubMed ID: 32798428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
